Rocket Lab USA, the launch and space systems company, presented a financial picture of robust growth tempered by a significant technical delay in its latest earnings report. While the company posted record annual revenue, investor attention was quickly captured by news that the inaugural launch of its next-generation Neutron rocket would be pushed back.
Financial Strength Meets Development Hurdle
The company announced full-year 2025 revenue of $602 million, representing a substantial 38% increase over the prior year. The fourth quarter contributed $179.65 million to that total, slightly surpassing market expectations of $178.47 million. On a per-share basis, the quarterly loss was reported at $0.09, a marginal improvement over the anticipated $0.10 loss.
Discrepancies emerged in the earnings-per-share analysis depending on the data source. One assessment pointed to a GAAP miss, with an actual result of –$0.09 per share against an expectation of –$0.01. However, other data sets, including from Alpha Vantage, had estimated the quarterly loss at –$0.09, which would place the result precisely in line with forecasts.
Neutron Program Timeline Slips Due to Test Anomaly
The solid financial figures were overshadowed by a development setback in the Neutron program. During a qualification test, a crack was discovered in the Stage-1 tank. Company officials attributed the flaw to a manufacturing defect in a manually produced component. In response, Rocket Lab has transitioned the production process to an Automated Fiber Placement (AFP) method.
This incident has a tangible impact on the schedule. The maiden flight of the Neutron rocket is now targeted for the fourth quarter of 2026, a delay from the previously planned launch window in the first half of that year. The postponement extends the development and investment phase, increasing near-term pressure on cash flow and losses as testing and development expenditures rise.
In alignment with this shift, management provided guidance for the first quarter of 2026 anticipating lower GAAP gross margins compared to the strong fourth quarter. The forecast ranges from 34% to 36% (or 39% to 41% on a non-GAAP basis). Revenue for Q1 2026 is projected to be between $185 million and $200 million. Concurrently, the company expects an adjusted EBITDA loss of $21 million to $27 million.
Should investors sell immediately? Or is it worth buying Rocket Lab USA?
Backlog and Defense Contracts Provide Counterbalance
A significant counterweight to the Neutron delay is the company’s growing order book. Rocket Lab’s backlog surged 73% year-over-year to reach $1.85 billion. A major component of this is an $816 million contract awarded by the Space Development Agency.
A notable trend in Q4 was that product revenue exceeded service revenue for the first time, indicating a reduced reliance on pure launch business. Research and development spending also saw a marked increase, climbing to $78.8 million from $48.3 million in the same quarter the previous year.
Operationally, Rocket Lab demonstrated progress in the defense sector. On February 27, 2026, it successfully launched the hypersonic test mission “That’s Not A Knife” using its HASTE rocket for the Defense Innovation Unit (DIU). This mission marked the second DIU hypersonic test within three months, the 7th HASTE launch, and the company’s 82nd overall launch. The firm completed seven missions in the fourth quarter alone, achieving a 100% success rate across 21 launches for the full year 2025.
Navigating the Financial and Operational Path Forward
Rocket Lab’s financial position includes liquidity of approximately $1.1 billion, which incorporates $280.6 million generated from at-the-market (ATM) equity sales. Despite this strong balance sheet, management cautioned investors to expect continued negative free cash flow and elevated capital investments, driven primarily by the Neutron program and the SDA contract work.
A key focus for observers will be whether the company can execute its stated plan to shift the cost center from research and development toward flight inventory in 2026—a move that would signal Neutron’s approach to its debut launch. The next regular financial update is scheduled for May. Company leadership indicated that the first quarter of 2026 should represent the peak for Neutron-related R&D spending.
Ad
Rocket Lab USA Stock: Buy or Sell?! New Rocket Lab USA Analysis from March 24 delivers the answer:
The latest Rocket Lab USA figures speak for themselves: Urgent action needed for Rocket Lab USA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 24.
Rocket Lab USA: Buy or sell? Read more here...










